- Home
- QCLS vs IGC Comparison
QCLS vs IGC Comparison
Compare QCLS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QCLS | IGC |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6M | 28.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | QCLS | IGC |
|---|---|---|
| Price | $4.08 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | ★ 836.6K | 301.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.50 | $0.24 |
| 52 Week High | $8.17 | $0.50 |
Technical Indicators
Market Signals| Indicator | QCLS | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 55.97 |
| Support Level | $4.00 | N/A |
| Resistance Level | $4.57 | $0.32 |
| Average True Range (ATR) | 0.38 | 0.02 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 42.77 | 55.00 |
Price Performance
Historical ComparisonAbout QCLS Q/C Technologies Inc.
Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.